

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission 18

Application Number	10/627,931
Filing Date	August 28, 2005
First Named Inventor	BOT, Adrian
Art Unit	1633
Examiner Name	WEIHE, Anne Marie Sabrina
Attorney Docket Number	8114-008-WO-US

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): -Assignee showing of ownership per 37 CFR 3.73, including Exhibits A, B, and C
Remarks 		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Catalyst Law Group, APC		
Signature			
Printed name	David M. Kohn, J.D.		
Date	April 23, 2007	Reg. No.	53,150

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Elizabeth McDonald	Date	April 23, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Mail Stop: Assignment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 3.73

Sir:

In connection with the above-referenced patent application, please enter the following statement under 37 C.F.R. § 3.73.

Applicant: **MultiCell Immunotherapeutics, Inc.**

Application No.: 10/527,931 Filed: 08/26/2005

Entitled: Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells.

MultiCell Immunotherapeutics, Inc., a Delaware corporation, states that it is:
the assignee of the entire right, title, and interest in the patent application identified above by virtue of a chain of title from the inventors, of the patent application identified above, to the current assignee as shown below:

1. Assignment from inventors Adrian Bot, Lilin Wang, Dan Smith, and Bill Phillips to Alliance Pharmaceutical Corporation, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 013522, Frame 0312.
2. Assignment from Alliance Pharmaceutical Corporation, Inc., and Astral, Inc., to Astral Therapeutics, Inc. A copy thereof is attached as Exhibit "A" and the serial number of the above-referenced application is highlighted for convenience.
3. Statement by Jack DeFranco, President and CEO of Alliance Pharmaceutical Corporation, Inc., stating that Astral, Inc., is a fully-owned subsidiary of Alliance Pharmaceutical Corporation, Inc. A copy thereof is attached herein as Exhibit "B".


4. Name change of Astral Therapeutics, Inc. to **MultiCell Immunotherapeutics, Inc.** A copy of the Certificate of Name Change is attached herein as Exhibit "C".

Assignee, MultiCell Immunotherapeutics, Inc., respectfully requests entry of this statement under 37 C.F.R. § 3.73 and recordation of the assignment from Alliance Pharmaceutical Corporation, Inc., and Astral, Inc., to MultiCell Immunotherapeutics, Inc., attached herein as Exhibit "A".

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Date:

Aug 30, 2006



Dr. Stephen M. Chang
President and CEO

MultiCell Immunotherapeutics, Inc.
9710 Scranton Road, Suite 170
San Diego, CA 92121
Phone: (858) 200-0587
Fax: (858) 450-9834

EXHIBIT
A

ASSIGNMENT OF PATENT RIGHTS



For good and valuable consideration, the receipt of which is hereby acknowledged, Astral, Inc., a Delaware corporation, and Alliance Pharmaceutical Corp., a New York corporation (together, the "Assignors"), do hereby assign, transfer and convey unto Astral Therapeutics, Inc., a Delaware corporation ("Assignee") or its designees, all of Assignors' right, title and interest in and to the patent applications and patents listed below, any patents issuing on any patent applications listed in Schedule A below, the inventions disclosed in any of the foregoing, any and all counterpart United States, International and foreign patents, applications and certificates of invention based upon or covering any portion of the foregoing and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part of any of the foregoing (collectively "Patent Rights"):

Assignors represent, warrant and covenant that: (i) they are the sole owners, assignees and holders of record title to the Patent Rights identified above, (ii) they have obtained and properly recorded previously executed assignments for all patent applications and patents identified above as necessary to fully perfect their rights and title therein in accordance with governing law and regulations in each respective jurisdiction, and (iii) they have full power and authority to make the present assignment. Assignors shall indemnify and hold harmless Assignee for any breach of the foregoing.

Assignors further agree to and hereby do assign, transfer and convey unto Assignee all rights: (i) in and to causes of action and enforcement rights for the Patent Rights including all rights to pursue damages, injunctive relief and other remedies for past and future infringement of the Patent Rights, and (ii) to apply in any or all countries of the world for patents, certificates of invention or other governmental grants for the Patent Rights, including without limitation under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other convention, treaty, agreement or understanding. Assignors also hereby authorize the respective patent office or governmental agency in each jurisdiction to issue any and all patents or certificates of invention which may be granted upon any of the Patent Rights in the name of Assignee, as the assignee to the entire interest therein.

Assignors will, at the reasonable request of Assignee and without demanding any further consideration therefor, do all things necessary, proper, or advisable, including without limitation the execution, acknowledgment and recordation of specific assignments, oaths, declarations and other documents on a country-by-country basis, to assist Assignee in obtaining, perfecting, sustaining, and/or enforcing the Patent Rights. Such assistance shall include providing, and obtaining from the respective inventors, prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, powers of attorney, specifications, declarations or other papers and other assistance reasonably necessary for filing patent applications, complying with any duty of disclosure, and conducting prosecution, reexamination, reissue, interference or other priority proceedings, opposition proceedings, cancellation proceedings, public use proceedings, infringement or other court actions and the like with respect to the Patent Rights.

The terms and conditions of this Assignment shall inure to the benefit of Assignee, its successors, assigns and other legal representatives, and shall be binding upon Assignors, their successors, assigns and other legal representatives.

IN WITNESS WHEREOF this Assignment of Patent Rights is executed on September 2, 2006.*Heather L. Murray*
(Notarization Required)*Heather L. Murray*
(Notarization Required)

ASSIGNORS

Alliance Pharmaceutical Corp.

By: *Deane J. Roth*Name: *Deane J. Roth*Title: *President + CEO*

Astrai, Inc.

By: *Deane J. Roth*Name: *Deane J. Roth*Title: *President + CEO*

Diane S. Roth
Name

Sept. 2, 2005
Date


State of Arizona
County of Pima

On September 2, 2005, before me, Heather L. Murray
personally appeared Diane S. Roth

G personally known to me or G proved to me on the basis of satisfactory evidence, to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal,

Heather L. Murray
(Notary Public)




Name

Date

State of Arizona)County of Pima)On Sept. 2, 2005, before me, Heather L. Murray,
personally appeared Heather L. MurrayG personally known to me or G proved to me on the basis of
satisfactory evidence, to be the person whose name is
subscribed to the within instrument and acknowledged to me
that he/she executed the same in his/her authorized capacity,
and that by his/her signature on the instrument the person or
the entity upon behalf of which the person acted, executed
the instrument.

WITNESS my hand and official seal.

Heather L. Murray
(Notary Public)

ALLIANCE PATENTS AND PATENT APPLICATIONS SUMMARY

CONFIDENTIAL

Client Code	Country Application No. [Patent No.]	Title	Date Issued	Areas of Coverage
ALLIA 400PCT	P.C.T. (U.S.) PCT/US03/07995	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	FD = March 14, 2003 Priority = March 15, 2002 (Claims priority to Prov. 02-01 3/15/02 and Prov. 02-05 9/20/02) published 25 Sept 2003	Methods and compositions for enhancing a response to an antigen comprising administration of dsRNA.
ALLIA 400US1	U.S. 10/507942	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	FD = September 13, 2004 Priority = 3/15/02 and 9/20/02	Method claims to enhancing a T cell response to an antigen using dsRNA, methods of preventing high zone tolerance to a non-infectious antigen by administering dsRNA and a composition for enhancing an immune response comprising pA-pU, pI-pC, etc.
ALLIA 400JP	Japan Appl. No 2003-576589	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	FD = November 12, 2004 Priority = 3/15/02 and 9/20/02	Method claims to enhancing a T cell response to an antigen using dsRNA, methods of preventing high zone tolerance to a non-infectious antigen by administering dsRNA and a composition for enhancing an immune response comprising pA-pU, pI-pC, etc.
ALLIA 400VCN	China Appl. No. 03810917.4	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	Actual FD = November 15, 2004; Effective FD= March 14, 2003 Priority = 3/15/02 and 9/20/02	Method claims to enhancing a T cell response to an antigen using dsRNA, methods of preventing high zone tolerance to a non-infectious antigen by administering dsRNA and a composition for enhancing an immune response comprising pA-pU, pI-pC, etc.

ALLIANCE PATENTS AND PATENT APPLICATIONS SUMMARY

CONFIDENTIAL

Client Code	Country Application No. [Patent No.]	Title	Date Filed Date Issued	Areas of Coverage
ALLIA-400EPO	Europe (designating all countries) EPO Application No. 03714172.8	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	FD = September 13, 2004 Priority = 3/15/02 and 9/20/02	Method claims to enhancing a T cell response to an antigen using dsRNA, methods of preventing high zone tolerance to a non- infectious antigen by administering dsRNA and a composition for enhancing an immune response comprising pA:pU, pI:pC, etc.
ALLIA-400AU	Australia Applic. No. 2003218181	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	FD = October 11, 2004 Priority = 3/15/02 and 9/20/02	Method claims to enhancing a T cell response to an antigen using dsRNA, methods of preventing high zone tolerance to a non- infectious antigen by administering dsRNA and a composition for enhancing an immune response comprising pA:pU, pI:pC, etc.
ALLIA-400CA	Canada Applic. No. 2479187	Compositions and Methods to Initiate or Enhance Antibody and Majorhistocompatibility Class I or Class II-restricted T Cell Responses By Using Immunomodulatory, Non-coding RNA Motifs / BOT, WANG, DELLAMARY, SMITH, PHILLIPS	FD = September 14, 2004 Priority = 3/15/02 and 9/20/02	Method claims to enhancing a T cell response to an antigen using dsRNA, methods of preventing high zone tolerance to a non- infectious antigen by administering dsRNA and a composition for enhancing an immune response comprising pA:pU, pI:pC, etc.

ALLIANCE PATENTS AND PATENT APPLICATIONS SUMMARY

CONFIDENTIAL

Client Code	Country Application No. (Patent No.)	Title	Date Filed Date Issued	Areas of Coverage
ALLIA-403PCT ★ →	P.C.T. (U.S.) PCT/US2003/03018	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS	Sept 18, 2003 Earliest Priority = Sept. 20, 2002 (Claims priority to Prov. 02-05 and Allia-400PCT)	Covers (a) a method of generating an enhanced immune response (i.e., T cell) to an antigen delivered in an engineered immunoglobulin by the co-administration of dsRNA (srRNA); (b) methods of loading an APC to generate a T cell response against an antigen which is delivered by an immunoglobulin or portion thereof where the epitope is processed by antigen presenting cells resulting in effective loading of MHC Class I molecules creating a MHC Class I-peptide complex; (c) methods for immunization against a delivered antigen; (d) methods of controlling a tumor by stimulating an immune response to the tumor by delivering a tumor-associated epitope peptide in conjunction with dsRNA; (e) methods of preventing high zone to an antigen tolerance in a patient; (f) immunoglobulin backbone; (g) use of dsRNA as an adjuvant to antigens delivered with or without the use of immunoglobulins; (h) use of dsRNA to enhance an immune response to an antigen already present in the body; and (i) various other methods and uses.

ALLIANCE PATENTS AND PATENT APPLICATIONS SUMMARY

CONFIDENTIAL

Client Code	Country Application No. [Patent No.]	Title	Date Filed Date Issued	Areas of Coverage
ALLIA.403 US	United States Serial No. 10/507,942	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS	March 16, 2005	Method of generating a T cell response to an antigen in a patient comprising administering with an immunoglobulin with an epitope in conjunction with dsRNA; method of loading an APC in a patient by use of an Ig-peptide complex in conjunction with dsRNA; method of enhancing an immune response to an antigen in a patient in need comprising administering Ig-peptide with dsRNA.
ALLIA.403 CA	Canada Applic. No. 2499066	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS	March 15, 2005	Method of generating a T cell response to an antigen in a patient comprising administering with an immunoglobulin with an epitope in conjunction with dsRNA; method of loading an APC in a patient by use of an Ig-peptide complex in conjunction with dsRNA; method of enhancing an immune response to an antigen in a patient in need comprising administering Ig-peptide with dsRNA.
ALLIA.403 EPO	Europe (all available states) European Patent Applic. No. 0377951.7-2402	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS		Use of dsRNA in the manufacture of a medicament for enhancing an immune response in a patient, comprising administering Ig-P in conjunction with dsRNA to the patient.

ALLIANCE PATENTS AND PATENT APPLICATIONS SUMMARY

CONFIDENTIAL

Client Code	Country Application No. [Patent No.]	Title	Date Filed Date Issued	Areas of Coverage
ALLIA.403CN	China Applic. No. 03825298.8	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS		A composition for generating an enhanced T cell response in a patient to an antigen comprising an Ig-P and a dsRNA segment; a composition for loading an APC and generation an immune response comprising an Ig-P and dsRNA segment; a composition for enhancing an immune response to an antigen in a patient in need thereof comprising Ig-P and dsRNA.
ALLIA.403AU	Australia Applic. No. 2003276932	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS	April 7, 2005	Method of generating a T cell response to an antigen in a patient comprising administering with an immunoglobulin with an epitope in conjunction with dsRNA; method of loading an APC in a patient by use of an Ig-peptide complex in conjunction with dsRNA; method of enhancing an immune response to an antigen in a patient in need comprising administering Ig-peptide with dsRNA

ALLIANCE PATENTS AND PATENT APPLICATIONS SUMMARY


CONFIDENTIAL

Client Code	Country Application No. [Patent No.]	Title	Date Filed Date Issued	Areas of Coverage
ALLIA 403P	Japan Appl. No. 2004- 538491	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells/ BOT, WANG SMITH, PHILLIPS	March 16, 2005	A composition for generating an enhanced T cell response in a patient to an antigen comprising an Ig-P and a dsRNA segment; a composition for loading an APC and generation an immune response comprising an Ig-P and dsRNA segment; a composition for enhancing an immune response to an antigen in a patient in need thereof comprising Ig-P and dsRNA.
ALLIA 405PCT	P.C.T. (U.S.) PCT/US2004/00926 1	Selected RNA Motifs to Induce Cell Death and/or Apoptosis/	March 25, 2004 (claims priority to Prov. 03-01 and Prov. 03-02 to March 26, 2003 and August 26, 2003)	Claims a method to inducing apoptosis or cell death in a transformed or non-transformed cell by the administration of dsRNA, methods of inducing apoptosis or cell death by administering siRNA or dsRNA less than 20Kda in size, 10Kda in size, and methods for inducing apoptosis or cell death in transformed cells by use of oligonucleotides wherein the oligonucleotide is comprised of base pairs selected from the group consisting of A, U, C, G and I.
ALLIA 406PR	U.S. Provisions;	Methods and Compositions to Generate and Control the Effector Profile of T Cells by Simultaneous Loading and Activation of Selected Subsets of Antigen Presenting Cells	August 17, 2005	Claims methods of tolerization and compounds comprising human IgG linked to at least one peptide epitope such as CAD or INSE.

EXHIBIT
B




I, Jack DeFranco, president and chief operating officer of Alliance Pharmaceutical Corp., do hereby certify that Astral, Inc., a Delaware corporation, is a fully-owned subsidiary of Alliance Pharmaceutical Corp. Astral was incorporated in the state of Delaware on April 3, 1987.

By: 
Jack DeFranco
President and Chief Operating Officer

State of California }
County of San Diego }

On January 24, 2006 before me, Leeanne Lawlor, personally appeared Jack DeFranco, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.



Notary Public

Print Name: LEEANNE LAWLOR

My commission expires:

03 - 22 - 09



EXHIBIT
C

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF "ASTRAL THERAPEUTICS, INC.", CHANGING ITS NAME FROM "ASTRAL THERAPEUTICS, INC." TO "MULTICELL IMMUNOTHERAPEUTICS, INC.", FILED IN THIS OFFICE ON THE EIGHTH DAY OF SEPTEMBER, A.D. 2005, AT 5 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



4017435 8100

050738155

Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 4143917

DATE: 09-09-05